Iovance Biotherapeutics, Inc. (IOVA)
Biological Products, (No Diagnostic Substances) · market cap $4.7B · as of 2026-08-14
Research and calibrated estimates, not financial advice — verify before acting.
- 2027-04-30 (est.)Phase 2 · Aldesleukinimp 7/10
- 2027-09-15 (est.)Phase 2 · IOV-4001imp 7/10
| Asset | Phase | Indication |
|---|---|---|
| LN-145 | Phase 2 | Metastatic Non Small Cell Lung Cancer |
| IOV-3001 | Phase 2 | Unresectable Melanoma |
| IOV-2001 | Phase 2 | Chronic Lymphocytic Leukemia |
| LN-145-S1 | Phase 2 | Squamous Cell Carcinoma of the Head and Neck |
| Lifileucel plus Pembrolizumab | Phase 3 | Metastatic Melanoma |
| Lifileucel | Phase 2 | Endometrial Cancer |
| IOV-4001 | Phase 2 | Unresectable Melanoma |
| Autologous Tumor Infiltrating Lymphocytes LN-145 | Phase 2 | Bone Sarcoma |
| E7 TCR-T cells | Phase 2 | Cervical Cancer |
| Aldesleukin | Phase 2 | HPV-Associated Cervical Carcinoma |
| Tumor infiltrating lymphocytes (TIL) LN-145 | Phase 2 | Metastatic Triple Negative Breast Cancer |
| Autologous Tumor Infiltrating Lymphocytes LN-145-S1 | Phase 2 | Bone Sarcoma |
Daily closes through 2026-11-04. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
- SEC filings — EDGAR filings for IOVA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 12 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.
